… colorectal cancer with cetuximab, we evaluated the shortterm efficacy of cetuximab and the
difference in efficacy of cetuximab as … were also multicenter studies with cetuximab as firstline …

… liver metastases: A randomised, phase II trial (PLANET-… metastases from colorectal cancer
with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter …

… for metastatic colorectal carcinoma (Stage IV … cetuximab, it was observed in a multicentre
phase II trial which indicated that the more pronounced the skin reaction (CTCAE V3.0 Grade 2 …

… Multicenter phase II and translational study of cetuximab in metastatic colorectal
carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24:4914-4921. …

… in the therapy of previously treated advanced colorectal cancer [ J] .Semin Oncol, 2005, 32(…
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma …

… and treatment of metastatic colorectal cancer (mCRC). Since … of metastatic colorectal cancer
(mCRC): Phase 2 results from … cetuximab in patients with advanced colorectal cancer (CRC) …

… half of patients have metastases, and about 25% of patients are diagnosed with colorectal
cancer in the advanced stage, focus metastasis. Metastatic colorectal cancer (mCRC) usually …

… and colorectal liver me-tastases (CRLM) can account for more than half of the progression of
colorectal cancer… , treatment methods and efficacy of translational therapy in CRLM, with the …

… Abstract Surgical resection is currently the only cure treatment for colorectal carcinoma liver
metastasis (CRLM). The efficiency of surgical resection has improved with the development …

… receptor (EGFR), such as panitumumab and cetuximab, has expanded the range of treatment
options for metastatic colorectal cancer. The realization that detection of positive EGFR …